WuXi PharmaTech Begins Construction On Manufacturing Facility In Philadelphia, Pennsylvania
04/29/2014
The new facility will consist of 45,000 square feet of clinical and commercial manufacturing space and will supplement WuXi's existing 16,000-square-foot cGMP cell therapy manufacturing facility.
Located in the Philadelphia Navy Yard, company officials said its new facility will complement WuXi's existing facility and capabilities which include analytical chemistry, cell banking, cell characterization, molecular biology and lot release testing, thereby providing fully integrated services for cell therapies in Philadelphia.
"Cell therapies offer important treatment options, and WuXi is committed to bringing them to patients faster," said Dr. Ge Li, Chairman/CEO of PharmaTech.
The company said “this expansion will support growing customer demand with single-source contract development and cGMP manufacture capabilities for allogeneic and autologous cell-based therapeutics. The new facility will be built using advanced modular design, with flexible clean room technology, disposable equipment, and microcarrier cell culture systems.”
Most Read
-
-
Trends in Office and Industrial Parks
Q4 2020
-
Another Look at Rural Economies
Q4 2020
-
Supply Chain Execs Respond as Pandemic Creates E-Commerce Surge
Q4 2020
-
Recruiting and Retaining Today’s Manufacturing Workforce
Workforce Q4 2020
-
The Future of the Workforce Is a “Better Normal”
Workforce Q4 2020
-
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
Q4 2019